Pharmacia clinical trials
Acquired by Pfizer, Apr 16, 2003 · source ↗
The registry lists 7 studies whose lead sponsor is Pharmacia. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 24, 2005.
- 7studies on the registry
- 0open to participants now
Before and after it joined Pfizer
- First submitted before Pharmacia became part of Pfizer
- 7
- First submitted after Pharmacia became part of Pfizer
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Pharmacia’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Rifabutin1 in phase 30 open · 6
- Ethambutol1 in phase 30 open · 2
- Clarithromycin1 in phase 30 open · 1
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed7100%
Registry sponsor names on this page
- Pharmacia7 studies
Something wrong with this grouping? Tell us on the Pfizer page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Pfizer studies →
- Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND StudyCompletedNCT00002080Not applicable
Sponsor listed in the registry: Pharmacia · First submitted before Pharmacia became part of Pfizer
- A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or PlaceboCompletedNCT00002101Phase 3
Sponsor listed in the registry: Pharmacia · First submitted before Pharmacia became part of Pfizer
- Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialCompletedNCT00002267Not applicable
Sponsor listed in the registry: Pharmacia · First submitted before Pharmacia became part of Pfizer
- A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected PatientsCompletedNCT00002435Phase 2
Sponsor listed in the registry: Pharmacia · First submitted before Pharmacia became part of Pfizer
- A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDSCompletedNCT00001995Not applicable
Sponsor listed in the registry: Pharmacia · First submitted before Pharmacia became part of Pfizer
- Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialCompletedNCT00002032Not applicable
Sponsor listed in the registry: Pharmacia · First submitted before Pharmacia became part of Pfizer
- A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDSCompletedNCT00002343Phase 4
Sponsor listed in the registry: Pharmacia · First submitted before Pharmacia became part of Pfizer